Introduction Autoimmune encephalitis associated with N-methyld-aspartate (NMDA) receptor antibodies is increasingly recognised in intensive care but there have been no reports of recurrent cases. Case A 22-year-old woman presented with in 2001 with generalised tonic clonic seizures followed by a progressive encephalopathy with confusion, fluctuating consciousness and impaired memory. Routine blood tests, auto-immune screen and serology were negative, CSF examination showed a pleocytosis and MRI revealed atrophy of the left hippocampus. She had a prolonged illness but made a slow recovery, returning to her premorbid level of functioning. She continued to suffer occasional seizures. She had a similar illness 13 years previously at the age of nine with encephalopathy, abdominal pain, headache, confusion and a hyperkinetic movement disorder. She again had made a slow but full recovery. No definitive cause for her illness had been found. Complement is known to play a key role in MS and recent work utilising proteomic analysis identified raised serum levels of C4a in patients compared to controls which decreased following relapse. In order to replicate and validate this finding which has significant implications for the pathogenesis of MS, we have measured serum C4 and C4a in 107 patients with representation from all disease subgroups and 40 controls. We also examined serial samples on 43 patients following relapse to assess dynamic changes. C4 levels showed good correlation with C4a (r¼0.27, p¼0.001). C4 levels were raised in MS patients (mean 267 mg/l, SD 116) compared to controls (mean 248 mg/l, SD 79; p<0.001) with no discrimination between disease subgroups. C4a levels were not significantly raised in primary (mean 1.40 mg/l, SD 0.67; p¼0.89) or secondary (mean 1.69 mg/l, SD 0.70; p¼0.18) progressive patients or relapsing remitting patients in remission (mean 1.39 mg/l, SD 0.79; p¼0.91) compared to controls; but were significantly increased in patients in acute relapse (mean 2.07 mg/l, SD 1.07; p<0.001) and decreased significantly after 2 months (mean 1.85 mg/l, SD 0.91; p¼0.028). In summary, we were able to confirm dynamic changes in C4a levels in patients in acute relapse implying a systemic humoural inflammatory component at relapse ignition; however, because of low sensitivity/specificity between patient groups it is unlikely that C4 or C4a could be employed as reliable clinical diagnostic or disease state biomarkers. Natalizumab reduces clinical relapses and the risk of sustained progression of disability in patients with relapsing remitting multiple sclerosis (RR MS). It has been associated with the development of progressive multifocal leucoencephalopathy, a rare demyelinating disease caused by JC virus. BK virus is a related polyomavirus known to cause morbidity in the immunocompromised host. Studies in the HIV population have linked BK viruria with immunodeficiency as evidenced by depressed CD4+ counts. We evaluated the relationship between the prevalence of JC and BK in MS patients receiving natalizumab and the degree of immunosuppression by sampling serum and urine specimens at baseline and at 3-monthly intervals. This is an ongoing prospective, longitudinal study that started in January 2007. A total of 86 subjects with active RRMS received natalizumab in our Department. We found no significant relationship between duration of natalizumab therapy and activation of JC virus. The risk of developing BK viruria, however, increased over time with the number of doses received. No significant reductions in CD4+ counts or in CD4+/CD8+ ratios were noted. These findings indicate that while there is a link between natalizumab and BK activation no significant immunosuppressive effect was observed. Further studies on the implications of BK virus in MS remain to be done but these results may have 
